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Abstract One-pot preparation of Na-protected amino/
peptide hydroxamic acids from corresponding carboxylic
acids is described using uronium-type coupling reagent
COMU. The present protocol is simple and mild conditions
are used. Thus the resulting hydroxamic acids are obtained
in good yields without racemization.
Keywords Na-protected amino/peptide acids  COMU 
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Introduction
Hydroxamic acids have received much attention as bio-
logically active compounds (Miller 1989; Kwak et al.
2011) and are well known to bind with hard metal ions
(Jung 2001; Dhungana et al. 2004). Molecules containing
this functional group serve as botulinum neurotoxin
(BoNT), tyrosinase and histone deacetylase (HDAC)
inhibitors. Adamantane hydroxamates were found to be
BoNT inhibitors, thus serve as valuable therapeutic tool for
the treatment of strabismus, migraines and even facial
wrinkles (Silhar et al. 2013) (Fig. 1). Hydroxycinnamoyl
phenylalanyl/prolyl hydroxamic acid derivatives have
emerged as tyrosinase inhibitors (Kwak et al. 2013) and
good antioxidants, which are useful in the fields of medi-
cine, agriculture and cosmetic industry (Fig. 2). HDAC
inhibitors were proven to fight against cancer and other
human afflictions including psychiatric, metabolic and
infectious diseases (Librizzi et al. 2012; Wagner et al.
2013) (Fig. 3).
Hydroxamic acids are the essential precursors for the
Lossen rearrangement to prepare carbamates, thiocarba-
mates and ureas (Yoganathan and Miller 2013; Vasantha
et al. 2010; Yadav et al. 2012; Narendra et al. 2009). The
reported methods for the preparation of hydroxamic acids
include the reaction of O/N-protected hydroxylamines with
activated carboxylic acids (Tamaki et al. 1993; Altenburger
et al. 1992; Ando and Tsumaki 1983; Lee and Miller 1983;
Anilkumar et al. 2000). Coupling of carboxylic acids with
hydroxylamine in presence of cyanuric chloride (TCT)
(Giacomelli et al. 2003) and cyclic phosphonic anhydride
(PPAA or T3P) (Ech-Chahad et al. 2005; Basavaprabhu
et al. 2013) require longer duration (6–12 h) for comple-
tion. A one-step approach using ethyl chloroformate as
carboxylic activator is limited as its vapor is irritant to skin
and eyes (Reddy et al. 2000). Vasanthakumar and Sures-
hbabu (2003) reported MgO mediated synthesis of Na-
Fmoc protected amino acid hydroxamates from acid chlo-
rides but due to instability of the acid chloride, the protocol
could not be extended to N-Boc/Cbz-protected amino
acids. Competent methods for the synthesis of O-alkyl
hydroxamic acids include the treatment of carboxylic acids
with the coupling agent (phosphoric acid diethyl ester 2-
phenyl-benzimidazol-1-yl ester) (Kokare et al. 2007) and
the reaction of N-acyloxazolidinones with hydroxylamine
using samarium triflate (Sibi et al. 2002). In case of O-alkyl
hydroxamic acids, deprotection is necessary after acyla-
tion, which limits their synthetic utility in multistep syn-
thesis. In order to develop an alternative to the existing
Electronic supplementary material The online version of this
article (doi:10.1007/s10989-014-9397-9) contains supplementary
material, which is available to authorized users.
N. R. Panguluri  Basavaprabhu  V. V. Sureshbabu (&)
No. 109, Peptide Research Laboratory, Department of Studies in
Chemistry, Central College Campus, Bangalore University,
Dr. B. R. Ambedkar Veedhi, Bangalore 560 001, India
e-mail: sureshbabuvommina@rediffmail.com;
hariccb@hotmail.com; hariccb@gmail.com
123
Int J Pept Res Ther (2014) 20:377–384
DOI 10.1007/s10989-014-9397-9
protocols 1-[(1-(cyano-2-ethoxy-2-oxoethylidenami-
nooxy)-dimethylamino-morpholinomethylene)] methanea-
minium hexafluorophosphate (COMU, Fig. 4) (El-Faham
and Albericio 2010, 2011) as an acid activator has been
envisaged for the one-pot conversion of Na-protected
amino/peptide acids to hydroxamic acids.
El-Faham et al. (2009) investigated the third generation
uronium-type coupling reagent COMU, based on Oxyma
[ethyl 2-cyano-2-(hydroxyimino)acetate, Fig. 5]. Due to
the presence of morpholino group in conjugation with an
oxime derivative, COMU shows a less hazardous safety
profile and offers better results than benzotriazole based
reagents such as N-[(dimethylamino)-1H-1,2,3-triazolo-
[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium
hexafluorophosphate N-oxide (HATU) and N-[(1H-ben-
zotriazol-1-yl)(dimethylamino)methylene]-N-methylme-
thanaminium hexafluorophosphate N-oxide (HBTU). It
shows excellent solubility and remarkable stability in DMF
and NMP, which makes it ideally suited for solid phase
peptide synthesis (Malik et al. 2010; Chantell et al. 2012;
Hjorringgaard et al. 2012). It is equally prominent for
solution phase synthesis since by-products formed by
COMU are water soluble and can be separated by simple
extraction. Calorimetry assays (DSC and ARC data) indi-
cate that COMU is non-explosive. COMU has been
employed as an excellent choice of coupling reagent in
solution phase and solid phase peptide synthesis. Tyrrell
et al. (2011) synthesized Weinreb amides employing
COMU as a coupling reagent. Zhang et al. (2011) used the
similar protocol for the synthesis of rubescesin S. Synthesis
of O-acyl isodipeptides had been reported by our group
using COMU (Samarasimhareddy et al. 2012). The com-
bination of microwave irradiation with COMU for the
synthesis of Aib-enkephalin pentapeptide (Subiros-Funosas
et al. 2009) and cyclic RGD peptides (Yamada et al. 2012)
were reported. Hjelmgaard et al. (2011a, b) reported
arylopeptoids with both free acids and free amides at the
C-terminus and N-methylated cyclic peptides using
COMU. The use of COMU and Oxyma offer high-yield
couplings for the synthesis of N-methylated cyclic peptide
(NMe-IB-01212) (Marcucci et al. 2012). Deprotected,
hydrophobic peptide cross-linked polystyrene nanoparti-
cles were synthesized in inverse miniemulsion using
COMU (Maier et al. 2011).
Experimental
Materials and Methods
All solvents were freshly distilled before use. Amino acids
were used as received from Sigma-Aldrich Company. 1H
and 13C NMR spectra were recorded on a Bruker AMX 300
and 75 MHz respectively, with DMSO-d6 as an internal
standard. Mass spectra were recorded using high resolution
mass spectrometer (HRMS) Q-T of mass spectrometer.
Melting points were measured with Veego (Model: VMP-
DS) melting point apparatus and the samples were dried
under vacuum before analysis. All the reactions were
monitored using TLCs with precoated silica gel plates
purchased from Merck. Chiral HPLC analysis of isomers
was carried out by Agilent 1100 series, Lux 5u Amylose-2,
250 9 4.60 mm.
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General Procedure for the Synthesis of Na-Urethane
Protected Amino/Peptide Hydroxamic Acids 2, 4
To a solution of Na-urethane protected amino/peptide acid
(1.0 mmol) in DMF, DIPEA (1.0 mmol), COMU
(1.1 mmol) and NH2OH (1.3 mmol) were added at 0 C.
After completion of reaction as monitored by TLC
(1–1.5 h), the product was extracted into ethyl acetate. The
organic layer was washed with water (2 9 10 mL), satu-
rated NaCl solution (2 9 10 mL) and dried over anhydrous
Na2SO4. The solvent was removed under reduced pressure
to afford the product.
Spectral Data of Compounds 2, 4
Na-Cbz-Val-NHOH (2a)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 1.20 (d, 6H,
J = 6.6 Hz, CH(CH3)2), 2.58 (m, 1H, CH(CH3)2), 4.30 (d,
1H, J = 5.8 Hz, CHCH(CH3)2), 5.14 (s, 2H, CH2C6H5),
5.72 (s, 1H, NH Cbz), 7.16–7.28 (m, 5H, C6H5), 8.44 (s,
1H, NHOH); 13C NMR (75 MHz,.DMSO-d6): d (ppm) =
16.2, 33.0, 56.3, 61.6, 127.1, 128.6, 129.4, 140.8, 158.0,
164.6. HRMS m/z calcd for C13H18N2O4: 289.1164
[M?Na]?, found: 289.1160 [M?Na]?.
Na-Cbz-Ser-NHOH (2b)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 3.20 (s, 1H,
CH2OH), 3.75–3.77 (m, 2H, CH2OH), 4.18 (m, 1H,
CHCH2OH), 5.01 (s, 2H, CH2C6H5), 5.42 (s, 1H, NH
Cbz), 7.21–7.26 (m, 5H, C6H5), 8.22 (s, 1H, NHOH);
13C
NMR (75 MHz, DMSO-d6): d (ppm) = 51.6, 63.8, 66.0,
127.4, 127.9, 128.8, 140.8, 162.8, 176.7. HRMS m/z calcd
for C11H14N2O5: 277.08 [M?Na]
?, found : 277.0805
[M?Na]?.
Na-Cbz-Ala-NHOH (2c)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 1.44 (d, 3H,
J = 5.8 Hz, CHCH3), 4.14 (m, 1H, CHCH3), 5.16 (s, 2H,
CH2C6H5), 6.22 (s, 1H, NH Cbz), 7.20–7.36 (m, 5H,
C6H5), 8.04 (s, 1H, NHOH);
13C NMR (75 MHz, DMSO-
d6): d (ppm) = 19.8, 42.6, 74.4, 128.4, 128.9, 129.8, 148.6,
168.8, 184.6. HRMS m/z calcd for C11H14N2O4: 261.0851
[M?Na]?, found: 261.0848 [M?Na]?.
Na-Cbz-Thr-NHOH (2d)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 0.98 (d,
3H, J = 5.8 Hz, CHCH(OH)CH3), 3.52 (s, 1H,
CHCH(OH)CH3), 3.85 (m, 1H, CHCH(OH)CH3), 4.28 (d,
1H, J = 6.1 Hz, CHCH(OH)CH3), 5.48 (s, 2H, CH2C6H5),
5.96 (s, 1H, NH Cbz), 7.12–7.26 (m, 5H, C6H5), 8.56 (s, 1H,
NHOH); 13C NMR (75 MHz, DMSO-d6): d (ppm) = 19.4,
54.4, 68.4, 69.6, 125.2, 125.7, 127.0, 143.2, 158.2, 162.2.
HRMS m/z calcd for C12H16N2O5: 291.0957 [M?Na]
?,
found: 291.0962 [M?Na]?.
Na-Boc-Pro-NHOH (2e)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 1.32 (s,
9H, C(CH3)3), 1.80–1.89 (m, 4H, –NCH2CH2CH2–),
3.24–3.44 (m, 2H, –NCH2CH2CH2–), 4.16 (m, 1H,
–CH2CHN–), 8.22 (s, 1H, NHOH);
13C NMR (75 MHz,
DMSO-d6): d (ppm) = 26.8, 32.6, 34.0, 49.6, 66.8, 77.6,
161.0, 176.0. HRMS m/z calcd for C10H18N2O4: 253.1164
[M?Na]?, found: 253.1167 [M?Na]?.
Na-Boc-Asp(OBzl)-NHOH (2f)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 1.34 (s, 9H,
C(CH3)3), 3.21 (d, 2H, J = 5.8 Hz, CHCH2COOBzl), 4.42
(m, 1H, CHCH2COOBzl), 5.04 (s, 2H, CH2C6H5), 5.72 (s,
1H, NH Boc), 7.22–7.32 (m, 5H, C6H5), 8.22 (s, 1H,
NHOH); 13C NMR (75 MHz, DMSO-d6): d (ppm) = 26.8,
36.6, 47.6, 67.8, 77.6, 125.4, 125.8, 127.6, 142.4, 156.4,
167.8, 176.2. HRMS m/z calcd for C16H22N2O6: 361.1376
[M?Na]?, found: 361.1379 [M?Na]?.
Na-Boc-Phe-NHOH (2g)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 1.38 (s, 9H,
C(CH3)3), 2.80–2.92 (d, 2H, J = 5.8 Hz, CH2C6H5), 3.58
(m, 1H, CHCH2C6H5), 5.92 (s, 1H, NH Boc), 7.22–7.38 (m,
5H, C6H5), 8.12 (s, 1H, NHOH);
13C NMR (75 MHz,
DMSO-d6): d (ppm) = 27.4, 34.8, 55.4, 75.4, 124.0, 126.0,
127.6, 141.4, 166.8, 171.2. HRMS m/z calcd for C14H20N2O4:
303.1321 [M?Na]?, found: 303.1326 [M?Na]?.
Na-Boc-Leu-NHOH (2h)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 0.92 (d, 6H,
J = 6.8 Hz, CHCH2CH(CH3)2), 1.43 (s, 9H, C(CH3)3),
1.72 (m, 2H, CHCH2CH(CH3)2), 1.78 (m, 1H, CHCH2
CH(CH3)2), 4.58 (m, 1H, CHCH2CH(CH3)2), 5.96 (s, 1H,
NH Boc), 8.34 (s, 1H, NHOH); 13C NMR (75 MHz,
DMSO-d6): d (ppm) = 21.6, 22.2, 27.4, 41.4, 48.4, 75.5,
154.0, 164.6. HRMS m/z calcd for C11H22N2O4: 269.1477
[M?Na]?, found: 269.1482 [M?Na]?.
Na-Fmoc-Tyr-NHOH (2i)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 3.12–3.26 (d,
2H, J = 5.8 Hz, CHCH2C6H4OH), 4.08 (t, 1H, J = 6.6 Hz,
CH Fmoc), 4.26 (m, 1H, CHCH2C6H4OH), 4.38 (d, 2H,
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J = 6.6 Hz, CH2 Fmoc), 5.26 (s, 1H, CH2C6H4OH), 5.66
(brs, 1H, NH Fmoc), 6.46 (d, 2H, J = 6.2 Hz, CH2C6H4
OH), 6.74 (d, 2H, J = 6.2 Hz, CH2C6H4OH), 7.16–7.94
(m, 8H, Fmoc), 7.86 (s, 1H, NHOH); 13C NMR (75 MHz,
DMSO-d6): d (ppm) = 36.8, 46.6, 51.8, 67.8, 115.6, 126.6,
128.6, 128.8, 129.0, 129.6, 131.8, 141.8, 143.4, 155.2,
156.8, 168.2. HRMS m/z calcd for C24H22N2O5: 441.1426
[M?Na]?, found: 441.1422 [M?Na]?.
Na-Fmoc-Ile-NHOH (2j)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 0.83–0.87 (m,
6H, CHCH(CH3)CH2CH3), 1.20 (m, 2H, CHCH(CH3)
CH2CH3), 2.06 (m, 1H, CHCH(CH3)CH2CH3), 4.02 (m, 1H,
CHCH(CH3)CH2CH3), 4.14 (t, 1H, J = 6.0 Hz, CH Fmoc),
4.26 (d, 2H, J = 6.0 Hz, CH2 Fmoc), 5.30 (s, 1H, NH Fmoc),
7.19–7.71 (m, 8H, Fmoc), 8.48 (s, 1H, NHOH); 13C NMR
(75 MHz, DMSO-d6): d (ppm) = 11.2, 13.9, 25.8, 35.6,
45.0, 53.6, 68.4, 127.4, 129.2, 129.4, 129.8, 141.6, 143.8,
157.4, 167.8. HRMS m/z calcd for C21H24N2O4: 391.1634
[M?Na]?, found: 391.1639 [M?Na]?.
Na-Fmoc-Glu(OtBu)-NHOH (2k)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 1.37 (s, 9H,
C(CH3)3), 1.77–1.80 (m, 2H, –NCHCH2CH2–), 2.17–2.23
(m, 2H, –NCHCH2CH2–), 3.84 (t, 1H, J = 6.3 Hz, CH
Fmoc) 4.18–4.36 (m, 3H, CH2, Fmoc & –NCHCH2CH2–),
6.34 (s, 1H, NH Fmoc), 7.30–7.89 (m, 8H, Fmoc), 8.83 (s,
1H, NHOH); 13C NMR (75 MHz, DMSO-d6): d
(ppm) = 26.8, 27.4, 27.8, 43.0, 52.2, 65.6, 79.4, 127.4,
129.2, 129.4, 129.8, 139.8, 146.2, 155.5, 166.6, 174.2.
HRMS m/z calcd for C24H28N2O6: 463.1845 [M?Na]
?,
found: 463.1851 [M?Na]?.
Na-Fmoc-Phg-NHOH (2l)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 4.12 (t, 1H,
J = 6.0 Hz, CH, Fmoc), 4.20 (d, 2H, J = 6.0 Hz, CH2,
Fmoc), 4.68 (s, 1H, CHC6H5), 5.17 (s, 1H, NH Fmoc),
7.18–7.69 (m, 13H, Fmoc & Ph), 8.75 (s, 1H, NHOH); 13C
NMR (75 MHz, DMSO-d6): d (ppm) = 48.2, 56.2, 68.2,
124.8, 125.5, 126.2, 126.4, 126.8, 127.3, 127.7, 135.8, 141.6,
142.8, 155.6, 169.2. HRMS m/z calcd for C23H20N2O4:
411.1321 [M?Na]?, found: 411.1324 [M?Na]?.
Na-Fmoc-Ala-Ile-NHOH (4a)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 0.86–1.02 (m,
6H, 2CH3, Ile), 1.28 (m, 2H, CHCH(CH3)CH2CH3), 1.32
(d, 3H, J = 5.6 Hz, CHCH3, Ala), 2.14 (m, 1H,
CHCH(CH3)CH2CH3), 4.18 (t, 1H, J = 6.4 Hz, CH,
Fmoc), 4.41–4.58 (m, 3H CHCH(CH3)CH2CH3, CH2
Fmoc), 4.68 (m, 1H, CHCH3), 5.34 (brs, 1H, NH Fmoc),
6.51 (s, 1H, NH amide), 7.22–7.86 (m, 8H, Fmoc), 7.96
(s, 1H, NHOH); 13C NMR (75 MHz, DMSO-d6): d
(ppm) = 11.2, 14.4, 18.2, 23.8, 34.6, 46.8, 52.6, 53.8, 67.8,
125.6, 127.4, 128.6, 128.8, 141.8, 142.8, 154.0, 162.2,
174.6 . HRMS m/z calcd for C24H29N3O5: 462.2005
[M?Na]?, found: 462.2003 [M?Na]?.
Boc-(L)-Phe-(D)-Phg-NHOH (4b)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 1.30 (s, 9H,
C(CH3)3), 3.36 (d, 2H, J = 5.9 Hz, CH2C6H5), 4.06 (m,
1H, CHCH2C6H5), 4.34 (s, 1H, CHC6H5), 5.32 (d, 1H,
J = 8.2 Hz, NH Boc), 7.06 (d, 1H, J = 8.2 Hz, NH amide),
7.18–7.36 (m, 10H, 2C6H5), 8.68 (s, 1H, NHOH);
13C NMR
(75 MHz, DMSO-d6): d (ppm) = 27.9, 37.2, 53.6, 56.0,
78.1, 126.1, 126.6, 127.5, 127.8, 128.1, 129.3, 138.0, 138.9,
155.5, 166.2, 171.5. HRMS m/z calcd for C22H27N3O5:
436.1848 [M?Na]?, found: 436.1846 [M?Na]?.
Boc-(L)-Phe-(L)-Phg-NHOH (4c)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 1.32 (s, 9H,
C(CH3)3), 3.38 (d, 2H, J = 5.9 Hz, CH2C6H5), 4.02 (m,
1H, CHCH2C6H5), 4.31 (s, 1H, CHC6H5), 5.37 (d, 1H,
J = 8.2 Hz, NH Boc), 7.02 (d, 1H, J = 8.2 Hz, NH amide),
7.20–7.36 (m, 10H, 2C6H5), 8.74 (s, 1H, NHOH);
13C NMR
(75 MHz, DMSO-d6): d (ppm) = 27.7, 37.2, 53.5, 56.3,
78.3, 126.4, 126.6, 127.5, 127.8, 128.1, 129.3, 138.2, 138.9,
155.4, 166.3, 171.6. HRMS m/z calcd for C22H27N3O:
436.1848 [M?Na]?, found: 436.1845 [M?Na]?.
Boc-Val-Leu-NHOH (4d)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 0.85-0.90 (m,
12H, 4CH3, Val, Ile), 1.35 (s, 9H, C(CH3)3), 1.43–1.57 (m,
2H, CHCH2CH(CH3)2, 1.90 (m, 1H, CHCH2CH(CH3)2),
3.76 (t, 1H, J = 7.2 Hz, CHCH2CH(CH3)2), 4.23 (m, 1H,
CHCH(CH3)2), 6.76 (d, 1H, J = 9.1 Hz, NH Boc), 7.78 (d,
1H, J = 8.3 Hz, NH amide), 8.84 (s, 1H, NHOH); 13C
NMR (75 MHz, DMSO-d6): d (ppm) = 16.1, 22.5, 24.8,
28.0, 33.1, 44.5, 48.9, 58.2, 78.0, 156.1, 168.2, 170.5.
HRMS m/z calcd for C16H31N3O5 : 368.2161 [M?Na]
?,
found: 368.2164 [M?Na]?.
Na-Cbz-Phe-Ala-NHOH (4e)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 1.26 (d, 3H,
J = 6.4 Hz, CHCH3), 2.86–3.14 (d, 2H, J = 5.8 Hz,
CHCH2C6H5), 4.50 (m, 1H, CHCH2C6H5), 4.66 (m, 1H,
CHCH3), 5.16 (s, 2H, CH2 Cbz), 6.2 (brs, 1H, NH Cbz),
6.8 (s, 1H, NH amide), 7.04–7.26 (m, 10H, 2C6H5), 7.62 (s,
1H, NHOH); 13C NMR (75 MHz, DMSO-d6): d
380 Int J Pept Res Ther (2014) 20:377–384
123
(ppm) = 16.4, 32.4, 47.4, 53.8, 63.4, 126.2, 127.4, 127.8,
127.9, 128.4, 129.2, 136.4, 140.4, 153.0, 167.4, 168.6.
HRMS m/z calcd for C20H23N3O5: 408.1535 [M?Na]
?,
found: 408.1539 [M?Na]?.
Na-Cbz-Ala-Ile-NHOH (4f)
1H NMR (300 MHz, DMSO-d6): d (ppm) = 0.64–0.98 (m,
6H, 2CH3, Ile), 1.14 (d, 3H, J = 5.8 Hz, CHCH3), 1.42 (m,
2H, CHCH(CH3)CH2CH3), 1.64 (m, 1H, CHCH(CH3)-
CH2CH3), 4.02 (m, 1H, CHCH3), 4.18 (m, 1H,
CHCH(CH3)CH2CH3), 4.98 (s, 2H, CH2C6H5), 6.92 (s, 1H,
NH Cbz), 7.26–7.34 (m, 5H, C6H5), 7.54 (d, 1H,
J = 8.3 Hz, NH amide), 8.94 (s, 1H, NHOH); 13C NMR
Table 1 Screening with various solvents and bases for 2j
FmocHN
OH
O NH2OH
Solvent
Base
Temp
FmocHN
NHOH
O
COMU
Entry Solvent Base Yield (%)c
1 CH3CN TEA
a 70
2 DMF TEAb 85
3 DMF NMMa 80
4 DMF DIPEAa 94
5 DMF DIPEAb 96
6 THF DIPEAa 75
7 THF TEAb 70
Bold entries indicate that the reaction gave maximum yield at that
condition
a 2.0 eq of base was used
b 1.0 eq of base was used
c Reaction was monitored for 1.0–1.5 h at 0 C using COMU
Table 2 List of amino
hydroxamic acids 2
S. 
No 
Hydroxamic 
acid (2) 
m.p. 
(oC) 
Yield 
(%) 
S. 
No 
Hydroxamic 
acid (2) 
m.p. 
(oC) 
Yield 
(%) 
a 
CbzHN
NHOH
O
Oil 94 g 
BocHN
NHOH
O
oil 96 
b 
CbzHN
NHOH
O
HO Oil 91 h 
BocHN
NHOH
O
gum 92 
c 
CbzHN
NHOH
O
Oil 93 i 
FmocHN NHOH
O
HO gum 92 
d 
CbzHN
NHOH
O
OH Oil 90 j 
FmocHN
NHOH
O
195 96 
e 
N
Boc O
NHOH Gum 95 k 
FmocHN NHOH
O
O O
96 94 
f 
BocHN
NHOH
O
OBn
O
82-83 90 l 
FmocHN
NHOH
O
132 95 
PgHN
R
OH
O
PgHN
R
NHOH
O
DIPEA, COMU
DMF, 0 oC
NH2OH
Pg= Fmoc/Boc/Cbz,
1 a-l 2 a-l
R=amino acid side chain
Scheme 1 Synthesis of amino hydroxamic acids 2
R1,R2=amino acid side chain
3 a-f
PgHN
R1 H
N
O R2
OH
O DIPEA, COMU
DMF, 0 oC
NH2OH
PgHN
R1 H
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(75 MHz, DMSO-d6): d (ppm) = 9.6, 14.2, 16.8, 23.8,
35.8, 51.2, 53.2, 68.4, 125.2, 125.7, 127.2, 143.6, 153.2,
164.2, 176.2. HRMS m/z calcd for C17H25N3O5: 374.1692
[M?Na]?, found: 374.1695 [M?Na]?.
Results and Discussion
Attracted by the wider utility, we investigated the use of
COMU for the one pot conversion of carboxylic acid to
hydroxamic acid. In a typical study, to a solution of Fmoc-
Ile-OH (1j) in CH3CN, TEA (2.0 eq), COMU (1.1 eq)
were added at 0 C. Then the activated carboxylic acid was
treated with a neutralized solution of NH2OHHCl (pre-
pared by neutralizing NH2OHHCl with methanolic KOH)
to obtain corresponding hydroxamic acid (70 %). In order
to improve the yield and to optimize the reaction condition,
various solvents and bases were screened. Delightly, DMF
and DIPEA found to be efficient reaction condition to
afford the desired hydroxamates in 96 % at 0 C (Table 1,
entry 5). Compared to existing protocols where 2–3 eq
base was required, in the present protocol one equivalent of
base was sufficient with COMU (El-Faham et al. 2009), as
the polar morpholino group in the reagent contributes as
internal base. The product Fmoc-Ile-NHOH (2j) was
extracted into ethyl acetate and isolated after simple
workup. One-pot synthesis of hydroxamic acids using
COMU is expedient and averts the ex-situ activation of
carboxylic acid processes (acid halides, esters etc.). Unlike
one-pot preparation of hydroxamic acids using TCT (Gia-
comelli et al. 2003) and PPAA (Ech-Chahad et al. 2005) it
proceeds in shorter duration (1–1.5 h).
Interestingly, when Na-protected Ser, Thr and Tyr were
subjected to hydroxyamidation under optimized conditions,
these amino acids afforded corresponding hydroxamates in
good yields without affecting free –OH (2b, 2d, 2i). It is
also endurable for the protecting groups like Fmoc/Boc/
Cbz as well as bifunctional amino acids. The generality of
the protocol was demonstrated for the synthesis of a series
of Na-urethane protected amino hydroxamic acids from
corresponding carboxylic acids (Scheme 1, Table 2).
The racemization study of the hydroxamates prepared
(Fmoc-L and D-Phg-NHOH, 2l and 2l*) using above
optimized conditions was undertaken as model compounds
and they showed peaks at Rt = 12.03 min (2l) and
Rt = 17.10 min (2l*) respectively. Also, intentionally
prepared equimolar mixture of L and D-Phg-NHOH
exhibited distinct peaks at Rt = 12.55 and 17.60 min (2l
and 2l*). These observations inferred that the protocol is
free from racemization and the hydroxamates were
obtained as optically pure isomers (method: n-hexane:
2-propanol (7:3); flow rate: 0.5 ml/min, 30 min).
Subsequently the similar protocol was exemplified for the
synthesis of peptide hydroxamic acids. Under the optimized
reaction conditions, Fmoc-Ala-Ile-OH 4a was treated with
DIPEA, COMU and NH2OH in DMF, the formation of
corresponding peptide hydroxamic acid was observed within
1.5 h. Even though literature shows that dipeptides in gen-
eral tend to racemize much more than amino acids, HPLC
analysis of L,D and L,L-N-(Boc)phenylalanyl-phenylgly-
cine hydroxamates 4b and 4c prepared from the above pro-
tocol showed that the dipetide hydroxamic acids were of
[99 % diastereomeric ratio. This indicates that no racemi-
zation has occurred at the a-centre during the hydroxamates
synthesis. Employing this protocol 4d, 4e and 4f were also
obtained in good yields. (Scheme 2, Table 3).
Conclusion
In outline, we have developed one-pot conversion of Na-
protected amino/peptide acids to hydroxamic acids
employing COMU as an acid activator and the protocol is
racemization free as evidenced by HPLC analysis. Unlike
other protocols for the preparation of hydroxamic acid, one
equivalent of base is sufficient as the morpholino group in the
reagent itself serves as internal base. In the present protocol,
the products were obtained in short duration, the byproducts
produced were all water soluble which makes isolation of the
products with high purity easier. The reaction can be moni-
tored visually by color change during the reaction and is
applicable for the synthesis of simple, bifunctional and ste-
rically hindered a-amino/peptide hydroxamic acids.
HPLC chromatographs of 2l, 2l* and mixture of 2l and
2l* and NMR (1H, 13C) spectra of 2, 4 were available in the
supporting information.
Table 3 List of peptide
hydroxamic acids 4
Entry Pg R1 R2 Yield (%) % of epimerization
4a Fmoc CH3 CHCH3CH2CH3 91
4b Boc (L)-CH2C6H5 (D)-C6H5 89 1.0
4c Boc (L)-CH2C6H5 (L)-C6H5 90 0.8
4d Boc CH(CH3)2 CH2CH(CH3)2 89 –
4e Cbz CH2C6H5 CH3 86 –
4f Cbz CH3 CHCH3CH2CH3 87 –
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